NCT06002438

Brief Summary

The goal of this clinical trial is to test egg powder supplementation in children with moderate acute malnutrition in Sierra Leone. The main question it aims to answer is: \- Will provision of 15g of whole egg powder per day during and after treatment for moderate acute malnutrition (for 24 weeks total) improve small intestinal permeability and linear growth among 6-30 month old Sierra Leonean children compared with daily corn powder supplementation?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
461

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2023

Geographic Reach
1 country

10 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 10, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 21, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

October 9, 2023

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 19, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 19, 2024

Completed
Last Updated

February 6, 2025

Status Verified

February 1, 2025

Enrollment Period

1.2 years

First QC Date

August 10, 2023

Last Update Submit

February 5, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Percent lactulose excretion

    Percent lactulose excretion in urine over \>=4 hours after lactulose consumption

    Collected 12 and 24 weeks after enrollment

  • Change in length-for-age z-score

    Difference in length-for-age z-score between enrollment and weeks 12 and 24

    To be compared at 12 and 24 weeks after enrollment

Secondary Outcomes (14)

  • Percent Lactulose excretion >= 0.2 and >=0.45

    Collected 6, 12, and 24 weeks after enrollment

  • Rate of length gain

    Across 24 week follow-up period

  • LAZ < -2

    To be compared at 12, 18, and 24 weeks after enrollment

  • Fecal host mRNA transcripts

    Collected 12 and 24 weeks after enrollment

  • Fecal host protein alpha-1 antitrypsin

    Collected 12 and 24 weeks after enrollment

  • +9 more secondary outcomes

Study Arms (2)

Egg powder

EXPERIMENTAL

15g egg powder per day for 24 weeks

Dietary Supplement: Whole egg powderDietary Supplement: Supercereal PlusDietary Supplement: Micronutrient sprinklesDrug: Sulfadoxine pyrimethamine

Corn powder

ACTIVE COMPARATOR

15g corn powder per day for 24 weeks

Dietary Supplement: Corn powderDietary Supplement: Supercereal PlusDietary Supplement: Micronutrient sprinklesDrug: Sulfadoxine pyrimethamine

Interventions

Whole egg powderDIETARY_SUPPLEMENT

15g daily dose for 24 weeks

Egg powder
Corn powderDIETARY_SUPPLEMENT

15g daily dose for 24 weeks

Corn powder
Supercereal PlusDIETARY_SUPPLEMENT

Approximately 110 g per day (1.5 kg every 2 weeks) supplementary food to be provided for treatment of MAM for up to 6 weeks.

Corn powderEgg powder
Micronutrient sprinklesDIETARY_SUPPLEMENT

To be provided after completion of MAM supplementary feeding. Provides 1 RDA of 14 micronutrients.

Corn powderEgg powder

Infants \< 12 months of age: 250/12.5mg SP at enrollment, week 6, week 12, week 18. Infants \>= 12 months of age: 500/25mg SP at enrollment, week 6, week 12, week 18.

Also known as: SP
Corn powderEgg powder

Eligibility Criteria

Age6 Months - 30 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • At least 6 months of age and less than 30 months of age
  • Mid-upper arm circumference \>= 11.5cm and \< 12. 5 cm
  • Mid-upper arm circumference-for-age z-score \< -2
  • Provision of signed (or thumb-printed) and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic

You may not qualify if:

  • Nutritional edema
  • Simultaneous involvement in another research trial or supplementary feeding program
  • Chronic debilitating illness
  • Allergy to egg
  • Receipt of treatment for acute malnutrition within 1 month prior to screening

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (10)

Bandajuma

Bandajuma, Southern Province, Sierra Leone

Location

Bendu Maleh

Bendu, Southern Province, Sierra Leone

Location

Blama Massaquoi

Blama Massaquoi, Southern Province, Sierra Leone

Location

Gbondapi

Gbondapi, Southern Province, Sierra Leone

Location

Gofor

Gofor, Southern Province, Sierra Leone

Location

Jendema

Jendema, Southern Province, Sierra Leone

Location

Potoru

Potoru, Southern Province, Sierra Leone

Location

Pujehun Static

Pujehun, Southern Province, Sierra Leone

Location

Taninahun

Taninahun, Southern Province, Sierra Leone

Location

Zimmi

Zimmi, Southern Province, Sierra Leone

Location

Related Publications (1)

  • Stephenson KB, Greenfeld A, Ryan MG, Kleban E, Kwak L, Lee A, Wegner DR, Jiang X, Hendrixson DT, Kamara MT, Koroma AS, Manary MJ. Egg supplementation for 24 weeks does not improve linear growth or reduce small intestinal permeability in Sierra Leonean children with moderate wasting: a randomized, blinded, controlled trial. Am J Clin Nutr. 2025 Nov;122(5):1326-1337. doi: 10.1016/j.ajcnut.2025.08.019. Epub 2025 Oct 14.

MeSH Terms

Conditions

Growth DisordersSevere Acute Malnutrition

Interventions

fanasil, pyrimethamine drug combination

Condition Hierarchy (Ancestors)

Pathologic ProcessesPathological Conditions, Signs and SymptomsMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Study Officials

  • Mark J Manary, MD

    Washington University School of Medicine

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
The intervention and control powders will be packaged such that investigators and outcomes assessors will not know their identity. Participants and care providers are likely to be able to distinguish them, however.
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2023

First Posted

August 21, 2023

Study Start

October 9, 2023

Primary Completion

December 19, 2024

Study Completion

December 19, 2024

Last Updated

February 6, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share
Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
Within 12 months of primary publication

Locations